BIO-A will take a while to become a real performer, we've only just got a marketing team together, and Bio-A is still in for a rerating as an actual medicine once Trials are completed, and don't forget Bioprospect doing the horse trials....you don't need TGA approval for animals......Those results should be be due soon, and another year or two should see better results on the human front. It has had exceptional results on Crohns disease and many other symptomatic conditions of the gut......just needs more marketing and and an upgrade to medicinal status, the could be as big as/bigger than Ropren.
I don't see current sales as a big problem, future sales are the winner.
If EPI is right we'll see our Ropren blues diminished within 2 weeks and the ANZ overhang gone.
We'll all look like geniuses once SLA gallops back to where it should be.
- Forums
- ASX - By Stock
- SLA
- value
value, page-3
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online